|
|
 |
|
Viewing report
|
|
|
|
Teva Pharmaceutical Industries Generics Company Intelligence Report
Espicom Business Intelligence Ltd, March 2009, Pages: 46
Teva is the largest generic pharmaceutical manufacturer in the world. This report provides an insight into the company, reviewing its current business structure and activities.
Teva is the largest generic pharmaceutical manufacturer in the world, with sales worth a record US$11.1 billion in 2008. The company is Israeli-owned and headquartered, although around 60% of revenues are gained in the USA.
In July 2005, Teva announced a merger with IVAX, one of the USA’s leading generic companies. The acquisition was completed in January 2006, in a deal worth some US$7.4 billion. The deal strengthened Teva’s position in the USA and Latin America.
The IVAX purchase followed a previous major deal. In November 2003, Teva announced the purchase of the US manufacturer, Sicor, for US$3.4 billion. This was the largest deal in the generic drug industry at the time. It gave Teva access to Sicor’s generic injectable products and biosimilar development capacity.
In 2008, Teva announced it was acquiring the US generic firm, Bentley Pharmaceuticals, in a deal worth some US$360 million. Although based in the US, Bentley’s main business was in Spain, with additional operations in other parts of Europe.
In July 2008, Teva Pharmaceutical Industries announced plans to acquire Barr in a deal worth some US$7.46 billion. The deal completed in December 2008, creating a company that operates in over 60 countries and employs some 37,000 people.
While the bulk of Teva’s revenues are derived from generics, the company has one major innovative product, Copaxone. This is a treatment for multiple sclerosis. Sales of Copaxone broke the US$1 billion mark in 2005, and were worth US$2.26 billion in 2008. A second innovative product, Azilect (rasagiline, Parkinson’s disease), was launched in 2006. Teva is also involved in research in other areas such as drug delivery and biosimilars.
This report provides information on the company's active product lines and ANDA approvals, along with a review of major developments, such as M&A activity, strategic alliances and litigation. The company's most recent quarterly and annual financial results are illustrated with comparative figures, charts and a detailed review of the data which allows you to track the company's progress.
Customers who bought this item also bought
Pharmavitae Generics - Teva
Teva Pharmaceutical Industries Ltd: PharmaVitae Model
Teva Partnering Guide 2008
Analysis of Teva Pharmaceutical Industries
Acquisition of Barr Pharmaceuticals Inc by Teva Pharmaceutical Industries Ltd Call - Barr Pharmaceuticals, Inc.,Teva Pharmaceutical Industries Ltd., - Earnings Transcript
Acquisition of Barr Pharmaceuticals Inc by Teva Pharmaceutical Industries Ltd Call - Barr Pharmaceuticals, Inc.,Teva Pharmaceutical Industries Ltd., - Earnings Transcript
Acquisition of Barr Pharmaceuticals Inc by Teva Pharmaceutical Industries Ltd Call - Barr Pharmaceuticals, Inc.,Teva Pharmaceutical Industries Ltd., - Earnings Transcript
The World Generic Market Report 2008
PharmaVitae 2001: Teva Pharmaceutical Industries
Teva Pharmaceutical Industries - SWOT Analysis - SWOT Analysis
Emerging Opportunities in Controlled-Release Generic Drugs
Teva Pharmaceutical Industries Limited - Financial and Strategic Analysis Review
|
|
|
|
